Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533624 · ClinicalTrials.gov registry record · Phase 2
Myfortic vs. Cellcept in Kidney Transplant Recipients
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00533624 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 150 participants.
The verdict
NCT00533624, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Mycophenolate Sodium Delayed Release Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533624
The ClinicalTrials.gov registry entry for NCT00533624 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00533624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533624 about?
NCT00533624 is a clinical study titled "Myfortic vs. Cellcept in Kidney Transplant Recipients". The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients.
What is the current status of trial NCT00533624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-12. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00533624?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Mycophenolate Sodium Delayed Release Tablets (DRUG).
Who is sponsoring clinical trial NCT00533624?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.